Enhanced T cell immune activity mediated by Drp1 promotes the efficacy of PD-1 inhibitors in treating lung cancer.

导出 OA

翻译打印收藏纠错

第一作者： Jietao,Ma

第一单位： Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, 110022, China.

作者： Jietao,Ma ^[1] ; Jun,Song ^[2] ; Xiaofang,Yi ^[1] ; Shuling,Zhang ^[1] ; Li,Sun ^[1] ; Letian,Huang ^[1] ; Chengbo,Han ^[3]

作者单位： Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, 110022, China. ^[1] Department of Oncology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, 441100, China. ^[2] Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, 110022, China. hanchengbo@sj-hospital.org. ^[3]

关键词 Dynamin-related protein 1 Immunotherapy Lung cancer Programmed cell death protein 1 T cells

主题词动物(Animals);人类(Humans);小鼠(Mice);CD8阳性T淋巴细胞(CD8-Positive T-Lymphocytes);动力蛋白质类(Dynamins);肺肿瘤(Lung Neoplasms)

DOI 10.1007/s00262-023-03582-5

PMID 38340166

发布时间 2024-02-28

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交